Author | Rrobert G. Petit, PhD


Alternative Dosing Schedules for Irinotecan

August 01, 1998

ByMace L. Rothenberg, MD|John G. Kuhn, PharmD|Larry J. Schaaf, PhD|Ronald L. Drengler, MD|S. Gail Eckhardt, MD|Miguel A. Villalona-calero, MD|Eric K. Rowinsky, MD|Daniel D. Von Hoff, MD|Langdon L. Miller, MD|Rrobert G. Petit, PhD|Lisa Hammond, MD

Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach